-
Posted by
Two Blokes Jun 16 -
Filed in
Stock
-
6 views
Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended debt maturities past 2027, giving management time to monetize assets and reduce leverage before Xifaxan's patent expires in 2028. Despite risks—$21.5B debt, Xifaxan patent cliff, and regulatory uncertainty—the company's strong revenue, EBITDA, and asset base support a 12-18 month target of $8-10 per share.
